{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:49:48Z","timestamp":1787791788782,"version":"build-2784847793"},"reference-count":31,"publisher":"The Pediatric Pharmacy Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"abstract":"\n OBJECTIVES<\/jats:title>\n American Congress of Obstetricians and Gynecologists recommends a single dose of antibiotic prophylaxis before all cesarean sections (C\/S). This recommendation is based on pharmacokinetic studies that include only non-obese patients. We sought to evaluate 1) cefazolin plasma concentrations among obese and non-obese patients after administration of a 2-g cefazolin dose for prevention of surgical wound infections, and 2) whether cefazolin concentration in fetal circulation may be protective against pathogens that cause early onset neonatal sepsis.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n Maternal and fetal cefazolin plasma concentrations were compared between obese (body mass index [BMI] \u2265 30 kg\/m2<\/jats:sup>) and non-obese (BMI < 25 kg\/m2<\/jats:sup>) healthy, term pregnant women undergoing scheduled C\/S. Liquid chromatographic\u2013tandem mass spectrometric (LC-MS\/MS) methods were used for quantification of total and free cefazolin concentrations in maternal blood (MB) and umbilical cord blood (UCB).<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n Eight women were screened and consented. There was no difference between groups in MB total and free cefazolin concentrations. All MB samples had total and free cefazolin concentrations greater than the minimum inhibitory concentration 90 (MIC90) for Group B Streptococcus<\/jats:italic> (GBS), Staphylococcus aureus<\/jats:italic>, and Escherichia coli<\/jats:italic>. All UCB samples had total and free cefazolin concentrations greater than MIC90 for GBS and S aureus<\/jats:italic>, even when administered as briefly as 18 minutes before delivery. A lower concentration of total cefazolin was detected in UCB of neonates of obese women compared to non-obese women (p > 0.05).<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n Administration of 2 g of cefazolin to women undergoing scheduled C\/S might be an adequate prophylactic dose for surgical wound infection in both non-obese and obese patients; and cefazolin concentration in fetal circulation may be protective against GBS and S aureus<\/jats:italic>.<\/jats:p>\n <\/jats:sec>","DOI":"10.5863\/1551-6776-22.3.227","type":"journal-article","created":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T20:56:26Z","timestamp":1497300986000},"page":"227-232","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Maternal Obesity on Maternal-Fetal Transfer of Preoperative Cefazolin at Cesarean Section"],"prefix":"10.5863","volume":"22","author":[{"given":"Stephanie McKenney","family":"Groff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wareef","family":"Fallatah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Crutchfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Kurtzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlton K.K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Burd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Farzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"suppl 1","key":"i1551-6776-22-3-227-b1","series-title":"Surg Infect (Larchmt)","first-page":"S9","article-title":"Surgical site infections: epidemiology and prevention","volume":"3","year":"2002","unstructured":"Barie\n PS\n . \n Surgical site infections: epidemiology and prevention. Surg Infect (Larchmt). 2002;3(suppl 1):S9\u2013S21."},{"issue":"4","key":"i1551-6776-22-3-227-b2","series-title":"Obstet Gynecol","first-page":"877","article-title":"Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery","volume":"117","year":"2011","unstructured":"Pevzner\n L\n , SwankM, KrepelC, \n et al. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol. 2011;117(4):877\u2013882."},{"issue":"3","key":"i1551-6776-22-3-227-b3","series-title":"Int J Gynaecol Obstet","first-page":"244","article-title":"Prophylactic ampicillin versus cefazolin for the prevention of post-cesarean infectious morbidity in Rwanda","volume":"124","year":"2014","unstructured":"Mivumbi\n VN\n , LittleSE, RulisaS, \n et al. Prophylactic ampicillin versus cefazolin for the prevention of post-cesarean infectious morbidity in Rwanda. Int J Gynaecol Obstet. 2014;124(3):244\u2013247."},{"issue":"7","key":"i1551-6776-22-3-227-b4","series-title":"Obstet Gynecol Surv","first-page":"462","article-title":"Management of wound complications from cesarean delivery","volume":"60","year":"2005","unstructured":"Sarsam\n SE\n , ElliottJP, LamGK. \n Management of wound complications from cesarean delivery. Obstet Gynecol Surv. 2005;60(7):462\u2013473."},{"key":"i1551-6776-22-3-227-b5","series-title":"Cochrane Database Syst Rev","first-page":"CD007482","article-title":"Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section","volume":"10","year":"2014","unstructured":"Smaill\n FM\n , GrivellRM. \n Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database Syst Rev. 2014;10:CD007482."},{"key":"i1551-6776-22-3-227-b6","series-title":"Biomed Res Int","first-page":"897216","article-title":"Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy","volume":"2014","year":"2014","unstructured":"van Hasselt\n JG\n , AllegaertK, van CalsterenK, \n et al. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. Biomed Res Int. 2014;2014:897216."},{"issue":"2","key":"i1551-6776-22-3-227-b7","series-title":"Am J Obstet Gynecol","first-page":"170.e171","article-title":"Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy","volume":"200","year":"2009","unstructured":"Allegaert\n K\n , van MieghemT, VerbesseltR, \n et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. Am J Obstet Gynecol. 2009;200(2):170.e171\u2013177."},{"issue":"6","key":"i1551-6776-22-3-227-b8","series-title":"Antimicrob Agents Chemother","first-page":"3504","article-title":"Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery","volume":"58","year":"2014","unstructured":"Elkomy\n MH\n , SultanP, DroverDR, \n et al. Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery. Antimicrob Agents Chemother. 2014;58(6):3504\u20133513."},{"issue":"5","key":"i1551-6776-22-3-227-b9","series-title":"Surg Infect (Larchmt)","first-page":"455","article-title":"Plasma and tissue cefazolin concentrations in obese patients undergoing cesarean delivery and receiving differing pre-operative doses of drug","volume":"14","year":"2013","unstructured":"Stitely\n M\n , SweetM, SlainD, \n et al. Plasma and tissue cefazolin concentrations in obese patients undergoing cesarean delivery and receiving differing pre-operative doses of drug. Surg Infect (Larchmt). 2013;14(5):455\u2013459."},{"issue":"6","key":"i1551-6776-22-3-227-b10","series-title":"Obstet Gynecol","first-page":"1472","article-title":"ACOG Practice Bulletin No. 120: use of prophylactic antibiotics in labor and delivery","volume":"117","year":"2011","unstructured":"American College of Obstetrics, Gynecologists. \n ACOG Practice Bulletin No. 120: use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2011;117(6):1472\u20131483."},{"issue":"2","key":"i1551-6776-22-3-227-b11","series-title":"Obstet Gynecol Clin North Am","first-page":"285","article-title":"Pregnancy and obesity","volume":"36","year":"2009","unstructured":"Yogev\n Y\n , CatalanoPM. \n Pregnancy and obesity. Obstet Gynecol Clin North Am. 2009;36(2):285\u2013300, viii."},{"issue":"2","key":"i1551-6776-22-3-227-b12","series-title":"Clin Perinatol","first-page":"375","article-title":"Group B streptococcal disease in infants: progress in prevention and continued challenges","volume":"37","year":"2010","unstructured":"Verani\n JR\n , SchragSJ. \n Group B streptococcal disease in infants: progress in prevention and continued challenges. Clin Perinatol. 2010;37(2):375\u2013392."},{"issue":"6","key":"i1551-6776-22-3-227-b13","series-title":"J Clin Pharm Ther","first-page":"595","article-title":"Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women","volume":"32","year":"2007","unstructured":"Popovic\n J\n , GrujicZ, SaboA. \n Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women. J Clin Pharm Ther. 2007;32(6):595\u2013602."},{"key":"i1551-6776-22-3-227-b14","series-title":"Inpharma","first-page":"19","article-title":"Cefazolin: maternal and transplacental pharmacokinetics","volume":"1321","year":"2002","unstructured":"Mitchell\n TF\n . \n Cefazolin: maternal and transplacental pharmacokinetics. Inpharma1321 (2002): 19."},{"issue":"10","key":"i1551-6776-22-3-227-b15","series-title":"J Clin Invest","first-page":"2592","article-title":"Untying the Gordian knot: policies, practices, and ethical issues related to banking of umbilical cord blood","volume":"115","year":"2005","unstructured":"Kurtzberg\n J\n , LyerlyAD, SugarmanJ. \n Untying the Gordian knot: policies, practices, and ethical issues related to banking of umbilical cord blood. J Clin Invest. 2005;115(10):2592\u20132597."},{"key":"i1551-6776-22-3-227-b16","series-title":"Practical Lab Med","first-page":"12","article-title":"Bioanalytical development and validation of liquid chromatographic\u2013tandem mass spectrometric methods for the quantification of total and free cefazolin in human plasma and cord blood","volume":"1","year":"2015","unstructured":"Crutchfield\n CA\n , MarzinkeMA. \n Bioanalytical development and validation of liquid chromatographic\u2013tandem mass spectrometric methods for the quantification of total and free cefazolin in human plasma and cord blood. Practical Lab Med. 2015;1:12\u201321."},{"issue":"11","key":"i1551-6776-22-3-227-b17","series-title":"Pediatr Infect Dis J","first-page":"937","article-title":"The burden of invasive early-onset neonatal sepsis in the United States, 2005\u20132008","volume":"30","year":"2011","unstructured":"Weston\n EJ\n , PondoT, LewisMM, \n et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005\u20132008. Pediatr Infect Dis J. 2011;30(11):937\u2013941."},{"key":"i1551-6776-22-3-227-b18","article-title":"Alert: antimicrobial susceptibility testing","year":"2016","unstructured":"Infectious Diseases Society of America. \n Alert: antimicrobial susceptibility testing. 2016. http:\/\/www.idsociety.org\/Topics_of_Interest\/Antimicrobial_Resistance\/Professionals\/Antimicrobial_Susceptibility_Testing\/. Accessed February 19, 2017."},{"issue":"3","key":"i1551-6776-22-3-227-b19","series-title":"Am J Obstet Gynecol","first-page":"938","article-title":"Placental transfer of cefazolin and piperacillin in pregnancies remote from term complicated by Rh isoimmunization","volume":"163","year":"1990","unstructured":"Brown\n CE\n , ChristmasJT, BawdonRE. \n Placental transfer of cefazolin and piperacillin in pregnancies remote from term complicated by Rh isoimmunization. Am J Obstet Gynecol. 1990;163(3):938\u2013943."},{"issue":"6","key":"i1551-6776-22-3-227-b20","series-title":"Obstet Gynecol","first-page":"1075","article-title":"Maternal and transplacental pharmacokinetics of cefazolin","volume":"98","year":"2001","unstructured":"Fiore Mitchell\n T\n , PearlmanMD, ChapmanRL, \n et al. Maternal and transplacental pharmacokinetics of cefazolin. Obstet Gynecol. 2001;98(6):1075\u20131079."},{"issue":"5","key":"i1551-6776-22-3-227-b21","series-title":"Clin Pharmacokinet","first-page":"328","article-title":"Pharmacokinetic changes during pregnancy and their clinical relevance","volume":"33","year":"1997","unstructured":"Loebstein\n R\n , LalkinA, KorenG. \n Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997;33(5):328\u2013343."},{"issue":"2","key":"i1551-6776-22-3-227-b22","series-title":"J Nutr Health Aging","first-page":"111","article-title":"A review of body water status and the effects of age and body fatness in children and adults","volume":"11","year":"2007","unstructured":"Chumlea\n WC\n , SchubertCM, SunSS, \n et al. A review of body water status and the effects of age and body fatness in children and adults. J Nutr Health Aging. 2007;11(2):111\u2013118."},{"key":"i1551-6776-22-3-227-b23","series-title":"Cardiovasc Res Cent Bull","first-page":"39","article-title":"Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity","volume":"1","year":"1962","unstructured":"Alexander\n JK\n , DennisEW, SmithWG, \n et al. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull. 1962;1:39\u201344."},{"issue":"10","key":"i1551-6776-22-3-227-b24","series-title":"Eur J Clin Pharmacol","first-page":"985","article-title":"Pharmacokinetics and protein binding of cefazolin in morbidly obese patients","volume":"67","year":"2011","unstructured":"an Kralingen\n S\n , TaksM, DiepstratenJ, \n et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011;67(10):985\u2013992."},{"issue":"3","key":"i1551-6776-22-3-227-b25","series-title":"J Antimicrob Chemother","first-page":"429","article-title":"Free and total cefazolin plasma and interstitial fluid concentrations at steady state during continuous infusion","volume":"50","year":"2002","unstructured":"Howard\n GW\n , BeggEJ, ChambersST, \n et al. Free and total cefazolin plasma and interstitial fluid concentrations at steady state during continuous infusion. J Antimicrob Chemother. 2002;50(3):429\u2013432."},{"issue":"2","key":"i1551-6776-22-3-227-b26","series-title":"Mayo Clin Proc","first-page":"187","article-title":"The cephalosporins","volume":"74","year":"1999","unstructured":"Marshall\n WF\n , BlairJE. \n The cephalosporins. Mayo Clin Proc. 1999;74(2):187\u2013195."},{"key":"i1551-6776-22-3-227-b27","series-title":"J Biomed Biotechnol","first-page":"783528","article-title":"Clinical therapeutics in pregnancy","volume":"2011","year":"2011","unstructured":"Feghali\n MN\n , MattisonDR. \n Clinical therapeutics in pregnancy. J Biomed Biotechnol. 2011;2011:783528."},{"issue":"2","key":"i1551-6776-22-3-227-b28","series-title":"Pediatr Clin North Am","first-page":"367","article-title":"Neonatal infectious diseases: evaluation of neonatal sepsis","volume":"60","year":"2013","unstructured":"Camacho-Gonzalez\n A\n , SpearmanPW, StollBJ. \n Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatr Clin North Am. 2013;60(2):367\u2013389."},{"issue":"5","key":"i1551-6776-22-3-227-b29","series-title":"Obstet Gynecol","first-page":"1205","article-title":"Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial","volume":"125","year":"2015","unstructured":"Maggio\n L\n , NicolauDP, DaCostaM, \n et al. Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial. Obstet Gynecol. 2015;125(5):1205\u20131210."},{"issue":"3","key":"i1551-6776-22-3-227-b30","series-title":"Am J Obstet Gynecol","first-page":"415.e411","article-title":"Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women","volume":"213","year":"2015","unstructured":"Swank\n ML\n , WingDA, NicolauDP, \n et al. Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. Am J Obstet Gynecol. 2015;213(3):415.e411\u2013418."},{"issue":"4","key":"i1551-6776-22-3-227-b31","series-title":"Am J Obstet Gynecol","first-page":"541.e1","article-title":"Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery","volume":"213","year":"2015","unstructured":"Young\n OM\n , ShaikIH, TwedtR, \n et al. Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. Am J Obstet Gynecol. 2015;213(4):541.e1\u20137."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/22\/3\/article-p227.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/22\/3\/227\/1787610\/1551-6776-22_3_227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/22\/3\/article-p227.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/22\/3\/article-p227.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:46:44Z","timestamp":1747356404000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/22\/3\/article-p227.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":31,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-22.3.227","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}